Kenichi Ishizawa

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Michinori Ogura, Takashi Ishida, Kiyohiko Hatake et al. · Journal of Clinical Oncology · 2014 · 361 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

Motoko Yamaguchi, Kensei Tobinai, Masahiko Oguchi et al. · Journal of Clinical Oncology · 2009 · 338 citations

Medicine, Oncology, Radiation Oncology +14

Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor–dependent pathway

Shigeru Shibata, Shengyu Mu, Hiroo Kawarazaki et al. · Journal of Clinical Investigation · 2011 · 232 citations

Medicine, Endocrinology, Nephrology +14